Activist Legion Partners Demands Full Cash Redemption of $12.5M Preferred Stock by Year-End
LFCR sits 40% above its 52-week low of $3.625.
Summary
Activist investor Legion Partners has formally demanded the cash redemption of all its Series A Preferred Stock, valued at approximately $12.5 million, by December 28, 2026, adding to the company's significant liquidity challenges.
Key Events · Ownership and Investor Activity · LFCR
-
Preferred Stock Redemption Demand
Legion Partners I and II formally demanded the cash redemption of all their Series A Preferred Stock holdings from Lifecore Biomedical.
-
Redemption Value
The preferred stock subject to redemption from Legion Partners is valued at approximately $12.5 million.
-
Redemption Deadline
The company is required to redeem these shares in cash by December 28, 2026.
-
Activist Pressure
Legion Partners, an activist investor holding 17.1% of common stock (including convertible preferred), is exerting significant financial pressure on the company.
Analysis · LFCR · Life Sciences
This Schedule 13D/A reveals that activist investor Legion Partners has formally demanded the cash redemption of its Series A Preferred Stock, totaling approximately $12.5 million, by December 28, 2026. This action places significant financial pressure on Lifecore Biomedical, especially as a concurrent 8-K filing indicates the company faces a total preferred stock redemption obligation of $52.1 million by year-end, which exceeds its current liquidity and will require additional financing. This demand from a major shareholder, representing 17.1% of common stock (including convertible preferred), signals a lack of confidence and creates a substantial cash outflow requirement for the company in the near term.
At the time of this filing, LFCR was trading at $5.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $190.9M. The 52-week trading range was $3.63 to $8.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.